The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

The data showed Tagrisso (osimertinib) slowed tumour progression compared with standard chemotherapy and was also more effective in patients with brain metastases – a group with a much worse ...

O n Wednesday, China approved AstraZeneca plc's (NYSE:AZN) Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy for the 1st-line treatment of adult patients with ...

AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating its position as the ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

The EC has now approved Tagrisso in combination with chemotherapy for the first-line treatment of advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) in adult patients whose tumors ...

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

Tagrisso is also approved in combination with chemotherapy in the US, China and several other countries for 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC. Each year, ...

TAGRISSO is approved for patients with EGFR mutations in the 1st-line metastatic setting as a monotherapy and in combination with chemotherapy, and as an adjuvant treatment for early-stage disease.

Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...

In March, the FDA approved the combination of Rybrevant and chemotherapy (carboplatin-pemetrexed ... Through these approvals, ...

Medscape Medical News, July 12, 2024 EU OKs First-Line Osimertinib+Chemo for EGFR+ Advanced NSCLC This decision is backed by results of the FLAURA2 trial, highlighting the efficacy of Tagrisso ...